Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer.

Erdoğar, N; Esendağlı, G; Nielsen, TT; Esendağlı-Yılmaz, G; Yöyen-Ermiş, DİĞDEM; Erdoğdu, B; Sargon, MF; Eroğlu, H; Bilensoy, E

doi:10.1080/1061186x.2017.1339194

Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer.

Erdoğar N., Esendağlı G., Nielsen T., Esendağlı-Yılmaz G., Yöyen-Ermiş D., Erdoğdu B., ...Daha Fazla

Journal of drug targeting, cilt.26, ss.66-74, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26
Basım Tarihi: 2018
Doi Numarası: 10.1080/1061186x.2017.1339194
Dergi Adı: Journal of drug targeting
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.66-74
Anahtar Kelimeler: Paclitaxel, nanoparticle, folate, amphiphilic cyclodextrin, breast cancer, IN-VIVO EVALUATION, DRUG-DELIVERY, CARBON NANOTUBES, TAXOL, FORMULATION, CELLS, VITRO, RELEASE, CAMPTOTHECIN, CHEMOTHERAPY
Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

Purpose: The aim of this study is to test folate-conjugated cyclodextrin nanoparticles (FCD-1 and FCD-2) as a vehicle for reducing toxicity and increasing the antitumor efficacy of paclitaxel especially for metastatic breast cancer.